Plain-English translation of NCT06007729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new cancer medication called given through an IV (intravenous) line. The study has two parts and will enroll about 170 people with head and neck cancer or other advanced cancers that have stopped responding to standard treatments or where patients couldn't tolerate those treatments. Researchers want to see if this medication is safe and effective.
People with advanced head and neck cancer and other solid tumors often run out of treatment options when standard therapies stop working or cause too many side effects. This medication is being tested because early work suggests it may help patients whose cancers have become resistant to other treatments.
You likely qualify if…
You likely don't qualify if…
You would receive as an intravenous infusion at a dose of 10 mg per kilogram of your body weight. You'll have regular visits to the clinic for treatment and monitoring, with careful follow-up for any side effects during treatment and for 90 days after your last dose. If the medication is working well and you're tolerating it, you may be able to continue receiving treatment with ongoing assessments to see how your cancer is responding.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China